Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0109)
Name
Thioctic acid
Synonyms
thioctic acid; dl-Thioctic acid; 1077-28-7; alpha-Lipoic acid; lipoic acid; 5-(1,2-Dithiolan-3-yl)pentanoic acid; 1,2-dithiolane-3-pentanoic acid; DL-alpha-Lipoic acid; alpha Lipoic Acid; Biletan; 62-46-4; 6,8-Thioctic acid; Thioctacid; DL-6,8-Thioctic acid; dl-Lipoic acid; 6-Thioctic acid; Lipothion; Liposan; Thioctsan; Tioctacid; Rac-lipoate; 1,2-Dithiolane-3-valeric acid; 6,8-Dithiooctanoic acid; alpha-Liponsaeure; DL-6-Thioctic acid; Thioctic acid dl-form; alpha-liponic acid; Thioktsaeure; Tioctidasi; (RS)-Lipoic acid; 5-(dithiolan-3-yl)pentanoic acid; 5-(1,2-Dithiolan-3-yl)valeric acid; espa-lipon; Acetate-replacing factor; 6,8-Thiotic acid; Thioctansaeure; 5-(Dithiolan-3-yl)valeric acid; (+-)-Lipoic acid; 6-Thiotic acid; .alpha.-Lipoic acid; DL-1,2-Dithiolane 3-valeric acid; thioctate; Thioctic acid [JAN]; Thioctsaeure; Thiocacid; Thioctan; liponic acid; Thiooctic acid; Lip(S2); a-lipoic acid; DL-.alpha.-Lipoic acid; Acidum thiocticum; (+/-)-1,2-Dithiolane-3-pentanoic acid; A-lipoicum acidum; DL-1,2-Dithiolane-3-valeric acid; lipoate; MFCD00005474; NSC 90788; Lipoic acid, alpha; Lipoic acid, dl-; NSC 628502; (+-)-1,2-Dithiolane-3-pentanoic acid; .alpha.-Liponic acid; CHEBI:16494; C8H14O2S2; DL-1,2-Dithiolan-3-valeriansaeure; (.+-.)-Lipoic acid; NSC-90788; (RS)-.alpha.-Lipoic acid; 5-[3-(1,2-dithiolanyl)]pentanoic acid; CHEMBL33864; DTXSID7025508; (.+-.)-.alpha.-Lipoic acid; 73Y7P0K73Y; 1,2-DITHIOLANE-3-VALERIC ACID, (+-)-; NSC90788; NSC-628502; Thioctic acid (JAN); NCGC00016032-06; Protogen A; (+/-)-alpha-Lipoic acid; Thiogamma; DTXCID705508; Thioktsaeure [German]; biomolipon; duralipon; Alipure; AlphaLipogamma; Thiotacid; biomo lipon; espa lipon; Alpha Lipogamma; Alpha-Lipogamma; Pyruvate oxidation factor; DL-Thiocticacid; Pleomix Alpha; Thioctacide T; Verla Lipon; AlphaLipon Stada; Alpha Lippon AL; alpha-Liponsaeure [German]; Alpha Lipon Stada; Alpha-Lipon Stada; 5-(1,2)Dithiolan-3-yl-pentanoic acid; 5-[1,2]Dithiolan-3-yl-pentanoic acid; Liponsaureratiopharm; alpha-lipon 300; SMR000058198; CAS-1077-28-7; Liponsaure-ratiopharm; (+-)-Thioctic acid; 5-(3-(1,2-DITHIOLANYL))PENTANOIC ACID; alpha Liponsaure von ct; Tioctidasi acetate replacing factor; (R)-(+)-alpha-Lipoic acid;R-(+)-Thioctic acid; SR-01000737460; DL-6,8-DITHIOOCTANOIC ACID; (RS)-alpha-Lipoic acid; EINECS 200-534-6; EINECS 214-071-2; (+-)-alpha-lipoic acid; BRN 0081853; BRN 0122410; UNII-73Y7P0K73Y; Alphalipoic-acid; DL-1,2-Dithiolan-3-valeriansaeure [German]; Thioctic acid [INN:BAN:JAN]; HSDB 7818; alpha-lipoic-acid; D,L-Lipoic acid; Thiotomin (TN); DL-a-Lipoic acid; D,L-Thioctic acid; lipoic acid (LA); alpha -Lipoic Acid; rac ?-Lipoic Acid; (RS)-thioctic acid; LIPOIC-ACID; ()-alpha-Lipoic acid; Spectrum_001618; 5-(1,2-dithiolan-3-yl)-pentanoate; Thioctic acid, dl-form; R-(+)-alpaLipoic acid; 1,2-Dithiolane-3-pentanoic acid, (+-)-; Spectrum2_001605; Spectrum3_001188; Spectrum4_000217; Spectrum5_001298; (S)-(-)-Thiocticacid; (+/-)-a-Lipoic acid; cid_864; (.+-.)-Thioctic acid; Lipoic acid, alpha [NF]; bmse000542; D0P6PQ; Epitope ID:150922; (+/-)-?-Lipoic acid; (.+/-.)-Lipoic acid; THIOCTIC ACID [MI]; SCHEMBL51065; BSPBio_002835; KBioGR_000853; KBioSS_002098; THIOCTIC ACID [HSDB]; THIOCTIC ACID [INCI]; 5-19-07-00237 (Beilstein Handbook Reference); MLS000069736; MLS001332379; MLS001332380; MLS002153365; DivK1c_000912; SPECTRUM1503941; SPBio_001609; THIOCTIC ACID [MART.]; THIOCTIC ACID [WHO-DD]; BDBM10515; HMS502N14; KBio1_000912; KBio2_002098; KBio2_004666; KBio2_007234; KBio3_002335; A-LIPOICUM ACIDUM [HPUS]; ALPHA LIPOIC ACID [VANDF]; ALPHA-LIPOIC ACID [VANDF]; NINDS_000912; thioctic acid (alpha-lipoic acid); HMS1922M22; HMS3649H08; HMS3885I16; Pharmakon1600-01503941; THIOCTIC ACID, (+/-)-; ALPHA LIPOIC ACID [USP-RS]; BCP13221; BCP14048; BCP18944; HY-N0492; THIOCTIC ACID DL-FORM [MI]; Tox21_110285; Tox21_201808; Tox21_303092; AC7875; BBL013878; CCG-39063; dl-1,2-Dithiolane-3-pentanoic acid; NSC628502; NSC758651; s3996; STK801969; THIOCTIC ACID [EP MONOGRAPH]; ()-1,2-Dithiolane-3-pentanoic acid; AKOS000121582; AKOS016339634; Tox21_110285_1; AB09328; AM84329; CS-4370; KS-1322; NSC-758651; SB49517; IDI1_000912; ALPHA LIPOIC ACID [USP IMPURITY]; NCGC00016032-02; NCGC00016032-03; NCGC00016032-04; NCGC00016032-05; NCGC00016032-07; NCGC00016032-08; NCGC00016032-09; NCGC00016032-11; NCGC00016032-14; NCGC00090872-01; NCGC00090872-02; NCGC00090872-03; NCGC00090872-04; NCGC00090872-05; NCGC00256970-01; NCGC00259357-01; (+/-)-alpha-Lipoic acid, >=98.0%; .ALPHA.-LIPOIC ACID, (+/-)-; AC-22673; BP-31070; NCI60_042014; R)-(+)-; A-Lipoic acid OOEthyAoEthAEa; SY010902; (R)-(+)-(c) paragraph sign-Lipoic acid; SBI-0051871.P002; 5-(1,2-Dithiolan-3-yl)pentanoic acid #; ( inverted exclamation markA)-a-Lipoic acid; 1,2-Dithiolane-3-valeric acid, (.+-.)-; FT-0622068; FT-0625429; FT-0670812; FT-0670813; L0058; 1,2-Dithiolane-3-pentanoic acid, (.+-.)-; 1,2-Dithiolane-3-valeric acid, (.+/-.)-; EN300-17612; 1,2-Dithiolane-3-pentanoic acid, (.+/-.)-; C00725; D00086; AB00052393_09; (+/-)?-?1,2-?Dithiolane-?3-?Pentanoic Acid; A801751; Q312229; 1,2-Dithiolane-3-pentanoic acid, (+-)- (9CI); J-002007; J-520421; SR-01000737460-2; SR-01000737460-6; 5-((3RS)-1,2-DITHIOLAN-3-YL)PENTANOIC ACID; Z56969297; F2191-0208; .DELTA.-(3-(1,2-DITHIACYCLOPENTYL))PENTANOIC ACID; Thioctic acid, European Pharmacopoeia (EP) Reference Standard; (+/-)-alpha-Lipoic acid, BioReagent, cell culture tested, >=99%; (+/-)-alpha-Lipoic acid, synthetic, >=99% (titration), powder; Alpha Lipoic Acid, United States Pharmacopeia (USP) Reference Standard; (R)-(+)-1,2-Dithiolane-3-pentanoic acid; R-(+)-Thioctic acid; R-(+)-alpha-Lipoic acid; AfAE'A centa' notA inverted exclamation markAfasA'A; AfAE'Adaggeratrade mark?-Lipoic Acid; Thioctic acid containing impurity B, European Pharmacopoeia (EP) Reference Standard; Thioctic acid for system suitability, European Pharmacopoeia (EP) Reference Standard; Thioctic Acid;1,2-Dithiolane-3-pentanoic acid;5-(1,2-Dithiolan-3-yl)valeric acid

    Click to Show/Hide
Status
Investigative
Drug Type
Small molecular drug
Structure
Formula
C8H14O2S2
IUPAC Name
5-(dithiolan-3-yl)pentanoic acid
Canonical SMILES
C1CSSC1CCCCC(=O)O
InChI
InChI=1S/C8H14O2S2/c9-8(10)4-2-1-3-7-5-6-11-12-7/h7H,1-6H2,(H,9,10)
InChIKey
AGBQKNBQESQNJD-UHFFFAOYSA-N
PubChem CID
864
TTD Drug ID
D0P6PQ
Full List of Ferroptosis Target Related to This Drug
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Parkinson disease ICD-11: 8A00
 Disease Info 
Responsed Regulator Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) Suppressor
 Regulator Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
PI3K-Akt signaling pathway hsa04151
Cell Process Cell ferroptosis
In Vitro Model PC12 cells Adrenal gland pheochromocytoma Rattus norvegicus CVCL_0481
Response regulation a-Lipoic acid (a-LA) suppressed cell viability decline and mitigated ferroptosis in an MPP-induced PC12 cell model of parkinson's disease (PD) via activating the PI3K/Akt/Nrf2 pathway. These results discovered a novel a-LA-based therapy for PD patients, and activating the PI3K/Akt/Nrf2 pathway might be developed as a promising therapeutic approach for PD.
Transferrin receptor protein 1 (TFRC)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [2]
Target for Ferroptosis Marker/Suppressor/Driver
Responsed Disease Alzheimer disease ICD-11: 8A20
 Disease Info 
Pathway Response Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
In Vitro Model hBCs (Brain cells)
In Vivo Model
The P301S transgenic mice [B6C3-Tg (Prnp-MAPT*P301S) PS19 Vle/J], originally obtained from the Jackson laboratory (Bar Harbor, ME, USA), were used as a model of tauopathy. The female mice at the age of 5 months were randomly allocated to three treatment groups (7 mice/group) corresponding to vehicle control, 3 mg/kg LA (T5625, Sigma, St. Louis, MO; the dosage was calculated everyday based on weight), and 10 mg/kg LA. LA was administered by intraperitoneal injection once per day (no injection was administered one day every three days), and vehicle control mice received physiological saline.

    Click to Show/Hide
Response regulation Alzheimer's disease (AD) is the most common neurodegenerative disease and is characterized by neurofibrillary tangles (NFTs) composed of Tau protein. a-Lipoic acid (LA) plays a role in inhibiting Tau hyperphosphorylation and neuronal loss, including ferroptosis. After LA administration, TFR expression level was downregulated while Fpn1 level was upregulated, thereby reducing the iron overload.
Solute carrier family 40 member 1 (SLC40A1)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [2]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Alzheimer disease ICD-11: 8A20
 Disease Info 
Pathway Response Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
In Vitro Model hBCs (Brain cells)
In Vivo Model
The P301S transgenic mice [B6C3-Tg (Prnp-MAPT*P301S) PS19 Vle/J], originally obtained from the Jackson laboratory (Bar Harbor, ME, USA), were used as a model of tauopathy. The female mice at the age of 5 months were randomly allocated to three treatment groups (7 mice/group) corresponding to vehicle control, 3 mg/kg LA (T5625, Sigma, St. Louis, MO; the dosage was calculated everyday based on weight), and 10 mg/kg LA. LA was administered by intraperitoneal injection once per day (no injection was administered one day every three days), and vehicle control mice received physiological saline.

    Click to Show/Hide
Response regulation Alzheimer's disease (AD) is the most common neurodegenerative disease and is characterized by neurofibrillary tangles (NFTs) composed of Tau protein. a-Lipoic acid (LA) plays a role in inhibiting Tau hyperphosphorylation and neuronal loss, including ferroptosis. After LA administration, TFR expression level was downregulated while Fpn1 level was upregulated, thereby reducing the iron overload.
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [3]
Target for Ferroptosis Suppressor
Responsed Disease Nanotoxicity ICD-11: N.A.
 Disease Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model BALB/3T3 cells Normal Mus musculus CVCL_0184
Response regulation CoNPs could induce the ferroptosis-like cell death through the enhancement of intracellular reactive oxygen species (ROS) level, cytoplasmic Fe2+ level, lipid peroxidation, and consumption of reduced glutathione (GSH) as well as inhibition of glutathione peroxidase 4 (GPX4) activity. Importantly, a-lipoic acid (ALA), a natural antioxidant with the capability to scavenge free radicals and chelate toxic metals, was found to efficiently alleviate nanotoxicity.
References
Ref 1 -Lipoic acid alleviates ferroptosis in the MPP(+) -induced PC12 cells via activating the PI3K/Akt/Nrf2 pathway. Cell Biol Int. 2021 Feb;45(2):422-431. doi: 10.1002/cbin.11505. Epub 2020 Dec 8.
Ref 2 -Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice. Redox Biol. 2018 Apr;14:535-548. doi: 10.1016/j.redox.2017.11.001. Epub 2017 Nov 7.
Ref 3 Alpha lipoic acid antagonizes cytotoxicity of cobalt nanoparticles by inhibiting ferroptosis-like cell death. J Nanobiotechnology. 2020 Oct 2;18(1):141. doi: 10.1186/s12951-020-00700-8.